Searched for
CDMO STOCKS INDIA
How PGIM India's Rs 112 crore Healthcare Fund picks CDMO stocks to generate alphaPGIM India Healthcare Fund generated a 22% return over the past year by over-allocating to high-growth segments like CDMO, specialty pharma...- Gland Pharma block deal: Fosun Pharma divests 99 lakh shares worth Rs 2,800 croreFosun Pharma sold a 6% stake in Gland Pharma for ₹2,800 crore via a block deal, reducing its holding to 45.77%. Major buyers included Kotak...
- Block deal alert! Gland Pharma shares fall 3% as 1.2 crore shares change hands in 2 block deals; promoter Fosun likely sellerGland Pharma shares fell after a significant block deal involving Fosun Pharma Industrial. The company's VSEZ facility received zero USFDA ...
- Symbiotec Pharmalab IPO Day 4: GMP at 29%, subscription reaches 5.31xSymbiotec Pharmalab's IPO saw strong investor demand, closing oversubscribed 71.26 times. The company aimed to raise Rs 1,757 crore through...
- Aragen Life Sciences files draft papers with Sebi to raise funds through IPOAragen Life Sciences has filed its DRHP with Sebi for an IPO comprising a Rs 800 crore fresh issue and an OFS. Proceeds will fund debt repa...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsGiven the possibility of hostilities resuming in the Gulf region, focus on risk management in the market. Why? Because fresh hostilities wi...
- ETMarkets Smart Talk | Time to rotate from expensive smallcaps to large caps? Saurabh Prasad weighs inIn an interaction with Kshitij Anand of ETMarkets, Saurabh Prasad, Head – Research Centre at Mirae Asset Sharekhan, said large caps are now...
- ETMarkets Smart Talk | Large caps look better for next 24 months, but hidden gems remain in smallcaps: Divam SharmaSharma sees a stronger case for large caps over the next 24 months, particularly given the steep valuation premium commanded by small caps.
- NFO Insight: Invesco India Pharma and Healthcare Fund opens for subscription. Right time to invest in pharma funds?Invesco India has unveiled an innovative pharma and healthcare fund tailored for investors seeking opportunities in India's burgeoning heal...
- Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 targetJefferies has initiated coverage on Anthem Biosciences with a Buy rating and Rs 1,050 target, implying around 20% upside. The brokerage is ...
- ETMarkets Smart Talk | Nifty enters ‘very attractive’ zone as earnings improve: Union AMC’s Sanjay BembalkarDespite muted foreign flows and persistent geopolitical uncertainties keeping a lid on the broader market, corporate earnings have remained...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsHere’s one thing to watch for in the next few weeks: How does the street treat disappointments in the mid-cap segment? If the reaction is l...
- Tube Investments of India shares surge 8% after Q1 earnings. What Motilal Oswal is sayingTube Investments of India shares surged after the company reported a 5% year-on-year decline in Q1FY27 profit to Rs 158.62 crore, despite a...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhat is volatility? There is, of course, a mathematical definition. Then there is the human definition, which is how investors feel it. In ...
- Zydus Lifesciences shares drop 3% after Q1 earnings. Here's why Nuvama upgraded rating, hiked targetShares of Zydus Lifesciences saw a decline of more than two percent following the announcement of a notable profit drop. The net profit plu...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsA word of caution for all those who have exposure to mid cap stocks or are planning to increase it. Just keep one thing in mind: If there i...
- Motilal Oswal raises mid and smallcap allocation to 50%, stays neutral on Indian equitiesMotilal Oswal Private Wealth favors Indian mid and small-cap stocks. They are increasing allocations to these segments by ten percentage po...
- Ashish Kacholia cuts stake in two chemical stocks after 114% rally. What's driving the move?Ace investor Ashish Kacholia has reduced holdings in two chemical stocks. Yasho Industries and Fineotex Chemicals saw stake reductions by t...
- Index returns likely to be slightly above long-term averages over next 2 years: Mirae Asset CIO Neelesh Surana on market outlook, fund strategiesMirae Asset Investment Managers (India)’s equity funds have experienced a period of underperformance—the first major blip since inception i...
Load More
